Unacylated tridecaptin A1 acts as an effective sensitiser of Gram-negative bacteria to other antibiotics

Highlights • H-TriA enhances activity of rifampicin and vancomycin against Gram-negative pathogens. • H-TriA is a tridecaptin (lipopeptide) derivative missing its N-terminal lipid tail. • H-TriA itself has low cytotoxicity, haemolytic activity and antimicrobial activity. • H-TriA is readily made by...

Full description

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2014-12, Vol.44 (6), p.493-499
Main Authors: Cochrane, Stephen A, Vederas, John C
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
Antibiotic
Campylobacter jejuni - drug effects
Cell Line
Cell Survival
Escherichia coli - drug effects
Gram-negative bacteria
Gram-Negative Bacteria - drug effects
Humans
Infectious Disease
Klebsiella pneumoniae - drug effects
Lipopeptide
Lipopeptides - pharmacology
Microbial Sensitivity Tests
Peptides - pharmacology
Rifampicin
Rifampin - pharmacology
Tridecaptin
Vancomycin
Vancomycin - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • H-TriA enhances activity of rifampicin and vancomycin against Gram-negative pathogens. • H-TriA is a tridecaptin (lipopeptide) derivative missing its N-terminal lipid tail. • H-TriA itself has low cytotoxicity, haemolytic activity and antimicrobial activity. • H-TriA is readily made by chemical synthesis and is stable in plasma.
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2014.08.008